Gerresheimer (ETR:GXI) target bumped up to 80.00EUR, issued a ratings update today by Hauck & Aufhäuser Privatbankiers KGaA
- Updated: October 4, 2016
Only yesterday Gerresheimer (ETR:GXI) traded 0.00% even at 76.14EUR. The company’s 50-day moving average is 0.00EUR and its 200-day moving average is 0.00EUR. The last closing price is up 0.00% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the date range. Volume of trade held steady, with 0 shares of GXI changing hands on par with the typical 0
In a statement issued on 10/04/2016 Hauck & Aufhäuser Privatbankiers KGaA increased the stock price target of Gerresheimer (ETR:GXI) to 80.00EUR indicating a possible upside of 0.05%.
Previously on 10/03/2016, Deutsche Bank AG reported about Gerresheimer (ETR:GXI) raised the target price from 0.00EUR to 73.00EUR. At the time, this indicated a possible downside of -0.04%.
With a total market value of 0 EUR, Gerresheimer has 52 week low of 0.00EUR and a 52 week high of 0.00EUR .
Brief Synopsis On Gerresheimer (ETR:GXI)
Gerresheimer AG is a Germany-based company that operates in the pharmaceuticals and health care industry. It is structured in three business segments: Plastic and Devices, Primary Packaging Glass and Life Science Research. The Company produces pharmaceutical packaging products, as well as drug-delivery systems made out of glass and plastics or a combination of both. Its product portfolio includes insulin pens, inhalers, pre-fillable syringes, vials, ampoules, bottles and containers for liquid and solid pharmaceuticals with closure and safety systems, plus cosmetic packaging products. The Company operates approximately 40 production facilities in Europe, North America, South America and Asia.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.